TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee

NEXT STORY
Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
PREV STORY
Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Cell Viability Assays & Consumables Market to 2023 – Increasing Focus on Development of Cell-Based Therapeutics & Potential Biomarkers

author_avatar
NASDAQ Market News

Alignment Health Plan Rolls Out New $0 Premium Medicare Advantage HMO, PPO and Dual-Eligible Plans to 600,000 North Carolina Seniors in 2022

author_avatar
NASDAQ Market News

Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City

NEWTOWN, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase ...

author_avatar
NASDAQ Market News